The China Mail - Trump’s Crackdown: Lives/Risk

USD -
AED 3.673031
AFN 69.999975
ALL 84.349738
AMD 383.82023
ANG 1.789699
AOA 916.999703
ARS 1371.507102
AUD 1.555694
AWG 1.8025
AZN 1.70046
BAM 1.708921
BBD 2.018218
BDT 122.195767
BGN 1.71186
BHD 0.37695
BIF 2942.5
BMD 1
BND 1.297101
BOB 6.907097
BRL 5.6089
BSD 0.999672
BTN 87.54407
BWP 13.649927
BYN 3.271194
BYR 19600
BZD 2.00782
CAD 1.38548
CDF 2890.000147
CHF 0.812399
CLF 0.024826
CLP 972.690362
CNY 7.19435
CNH 7.211215
COP 4185.74
CRC 505.122436
CUC 1
CUP 26.5
CVE 95.950118
CZK 21.515029
DJF 177.720063
DKK 6.534601
DOP 60.999434
DZD 130.922991
EGP 48.574497
ERN 15
ETB 138.203248
EUR 0.87545
FJD 2.272304
FKP 0.753407
GBP 0.757045
GEL 2.667185
GGP 0.753407
GHS 10.500971
GIP 0.753407
GMD 72.506005
GNF 8675.000116
GTQ 7.676882
GYD 209.126455
HKD 7.849985
HNL 26.349483
HRK 6.597398
HTG 131.169313
HUF 350.160011
IDR 16505.5
ILS 3.392025
IMP 0.753407
INR 87.5619
IQD 1310
IRR 42112.508216
ISK 124.489772
JEP 0.753407
JMD 159.943729
JOD 0.709039
JPY 150.691497
KES 129.519847
KGS 87.450088
KHR 4015.000027
KMF 431.515562
KPW 899.943686
KRW 1395.689952
KWD 0.30611
KYD 0.832958
KZT 539.837043
LAK 21580.000232
LBP 89549.999463
LKR 302.068634
LRD 201.000268
LSL 18.010273
LTL 2.95274
LVL 0.60489
LYD 5.415016
MAD 9.103983
MDL 17.212259
MGA 4429.999865
MKD 53.788855
MMK 2099.176207
MNT 3589.345014
MOP 8.082308
MRU 39.819929
MUR 46.198534
MVR 15.397809
MWK 1736.500534
MXN 18.83515
MYR 4.264994
MZN 63.959982
NAD 18.009717
NGN 1530.340293
NIO 36.750035
NOK 10.32407
NPR 140.070338
NZD 1.697745
OMR 0.384497
PAB 0.999585
PEN 3.569024
PGK 4.13025
PHP 58.200503
PKR 283.249829
PLN 3.74365
PYG 7486.402062
QAR 3.64075
RON 4.444903
RSD 102.580975
RUB 81.098596
RWF 1440
SAR 3.751155
SBD 8.244163
SCR 14.537798
SDG 600.499628
SEK 9.779905
SGD 1.29837
SHP 0.785843
SLE 22.999836
SLL 20969.503947
SOS 571.509608
SRD 36.815498
STD 20697.981008
STN 21.925
SVC 8.746368
SYP 13001.531245
SZL 18.009982
THB 32.780218
TJS 9.425981
TMT 3.51
TND 2.879813
TOP 2.342097
TRY 40.5936
TTD 6.786518
TWD 29.912901
TZS 2570.000052
UAH 41.696586
UGX 3583.302388
UYU 40.0886
UZS 12605.000133
VES 123.721575
VND 26199
VUV 119.302744
WST 2.758516
XAF 573.151008
XAG 0.02729
XAU 0.000304
XCD 2.70255
XCG 1.80154
XDR 0.69341
XOF 566.499098
XPF 104.924972
YER 240.650038
ZAR 18.214703
ZMK 9001.209359
ZMW 22.965115
ZWL 321.999592
  • SCU

    0.0000

    12.72

    0%

  • RBGPF

    0.3900

    74.42

    +0.52%

  • RYCEF

    1.0800

    14.18

    +7.62%

  • CMSC

    0.2500

    22.85

    +1.09%

  • BCC

    -1.0800

    83.81

    -1.29%

  • NGG

    0.2000

    70.39

    +0.28%

  • BCE

    -0.2000

    23.33

    -0.86%

  • CMSD

    0.2100

    23.27

    +0.9%

  • RIO

    0.2800

    59.77

    +0.47%

  • SCS

    0.0000

    10.33

    0%

  • JRI

    0.0200

    13.13

    +0.15%

  • RELX

    0.1100

    51.89

    +0.21%

  • VOD

    -0.2500

    10.81

    -2.31%

  • AZN

    -3.5000

    73.09

    -4.79%

  • BTI

    0.5200

    53.68

    +0.97%

  • GSK

    -1.8200

    37.15

    -4.9%

  • BP

    -0.1000

    32.15

    -0.31%


Trump’s Crackdown: Lives/Risk




In a dramatic push to tackle the skyrocketing cost of prescription drugs in the United States, President Donald Trump has taken decisive action against the pharmaceutical industry. With the stroke of a pen, he signed an executive order designed to slash drug prices, promising relief for millions of Americans burdened by exorbitant healthcare costs. However, this bold move has sparked fierce debate, with critics warning that the consequences could be catastrophic—potentially costing millions of lives due to drug shortages and stifled innovation.

Trump’s Plan to Lower Drug Prices
The executive order, enacted on May 12, 2025, seeks to align U.S. drug prices with those in other developed nations, where medications often cost a fraction of what Americans pay. Trump has long criticized the pharmaceutical industry for what he calls unfair pricing practices, arguing that U.S. consumers have been overcharged for years. The order aims to reduce prices by 30% to 80%, targeting both brand-name and generic drugs. It relies on voluntary compliance from drug companies, with the threat of future regulations looming if they fail to cooperate. For many patients, this could mean significant savings on medications that currently drain their finances.

The Dark Side: Drug Shortages Loom
While the goal of affordability is laudable, the plan has raised red flags among healthcare experts and industry leaders. One major concern is the risk of drug shortages. The U.S. already faces periodic shortages of critical medications, such as those used in cancer treatments and epidurals. Forcing pharmaceutical companies to lower prices could make it unprofitable to produce certain drugs, particularly low-cost generics. If production slows or stops, hospitals and pharmacies could struggle to secure enough supply, leaving patients without access to life-saving treatments. The ripple effect could be devastating, especially for vulnerable populations like cancer patients and the elderly.

A Blow to Innovation
Beyond immediate supply issues, the executive order could deal a severe blow to pharmaceutical innovation. Developing new drugs is an expensive and risky endeavor, often costing billions of dollars and taking years of research. The U.S. market, with its higher drug prices, has long been a key source of revenue for this work. If that revenue shrinks, companies may cut back on research and development, slowing the creation of new treatments for diseases like Alzheimer’s, cancer, and rare genetic disorders. A healthcare economist recently cautioned that such a move could “delay breakthroughs that millions of patients are counting on,” trading short-term savings for long-term losses in medical progress.

Economic Fallout
The economic implications are equally troubling. The pharmaceutical industry employs thousands of Americans and drives significant investment in the U.S. economy. Lower prices could lead to job cuts and reduced funding for new projects. One major drug company has already hinted at rethinking its $50 billion investment in the U.S. if the order takes full effect. While consumers might save money at the pharmacy, the broader economy could suffer as a result.

The Case for Change
Despite these risks, supporters argue that action is overdue. Prescription drug prices in the U.S. are nearly three times higher than in other advanced countries, forcing many Americans to ration their medications or skip doses entirely. Lowering prices could save billions of dollars and improve access for those with chronic conditions like diabetes or heart disease. For these patients, Trump’s order represents a lifeline—a chance to afford the drugs they need to survive.

A High-Stakes Gamble
As the dust settles, the debate rages on. Will Trump’s crackdown on the pharmaceutical industry deliver on its promise of affordable healthcare, or will it unleash a cascade of unintended consequences? The order’s success hinges on cooperation from an industry reluctant to sacrifice profits, and its failure could leave patients paying the ultimate price. For now, the nation watches as this high-stakes gamble unfolds, with millions of lives in the balance.